Megan Couvillion, MD
Dermatology · Houston, TXNPI 1760724157
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.0%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Pfizer at 48.4% of the total. Reporting peaked in 2024 at $55,201 and has fallen 62.3% since, to $20,818 in 2025. Among dermatology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 344 payments — averaging $269.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$45K
- Lilly USA, LLC$29K
- AbbVie$6K
- Dermavant Sciences, Inc.$4K
- Biofrontera Inc.$4K
- Novartis$954
- plus $4K from 25 others
Across 404 payments — averaging $7367.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$1.5M
- Eli Lilly$427K
- Janssen Research & Development, LLC$406K
- Amgen$201K
- Pfizer$155K
- Biofrontera Bioscience GmbH$137K
- plus $194K from 6 others
What the payments were for
- Consulting fees$25,07827%
- Speaking & faculty fees$51,03155%
- Travel & lodging$7,5748%
- Food & beverage$8,88010%
- Education$2220%
- Gifts$110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 53 | $44,959 |
| Lilly USA, LLC | 38 | $29,240 |
| AbbVie(2 entities) | 90 | $5,810 |
| Dermavant Sciences, Inc. | 7 | $3,792 |
| Biofrontera Inc. | 4 | $3,766 |
| Novartis | 30 | $954 |
| Galderma Laboratories, L.p. | 25 | $877 |
| Revance Therapeutics, Inc. | 11 | $728 |
| Johnson & Johnson | 15 | $610 |
| Biofrontera Bioscience GmbH | 3 | $524 |
| Amgen | 9 | $211 |
| Sanofi | 7 | $189 |
| Sun Pharmaceutical Industries Inc. | 7 | $163 |
| Merz North America, Inc. | 5 | $127 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 6 | $112 |
| LEO Pharma Inc. | 5 | $105 |
| E.r. Squibb & Sons, L.L.C. | 4 | $88 |
| UCB, Inc. | 3 | $86 |
| Incyte Corporation | 3 | $77 |
| Arcutis Biotherapeutics, Inc. | 3 | $67 |
| Dermira, Inc. | 2 | $60 |
| Janssen Research & Development, LLC | 1 | $52 |
| Journey Medical Corporation | 2 | $32 |
| Botanix SB Inc | 2 | $30 |
| Organon | 3 | $27 |
| Krystal Biotech Inc | 1 | $24 |
| Verrica Pharmaceuticals Inc. | 1 | $24 |
| VYNE Pharmaceuticals Inc. | 1 | $21 |
| Aclaris Therapeutics, Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $13 |
| Hill Dermaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$92,796 in reported general payments places this provider in the 90th percentile of 1,098 dermatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Taltz AutoinjectorIxekizumab | 13 | $91,499 |
| Ivermectin | 17 | $4,930 |
| Dutasteride | 60 | $1,615 |
| Finasteride | 137 | $1,069 |
| Ketoconazole | 50 | $747 |
| Clobetasol Propionate | 16 | $725 |
| ValacyclovirValacyclovir Hcl | 14 | $717 |
| Doxycycline Hyclate | 17 | $264 |
| Triamcinolone Acetonide | 22 | $215 |
| Hydroxychloroquine Sulfate | 27 | $208 |
| Minoxidil | 31 | $167 |
| Fluconazole | 11 | $90 |
| Mupirocin | 16 | $88 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Houston
- Alpesh DesaiHouston$1.6M
- Geeta PatelHouston$575K
- Michael MigdenHouston$310K
- Catherine PapasakelariouHouston$289K
- Stephen MahoneyHouston$137K
- Edward LainAustin$2.5M
- William CragunSan Antonio$2.2M
- Craig TellerBellaire$1.3M
- Jennifer CatherDallas$1.3M
- Emily BeckerSan Antonio$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.